Amgen sues Samsung biotech unit over bone drug copies
By Blake Brittain
Aug 13 (Reuters) -Amgen AMGN.O has sued Samsung's biologics unit 207940.KS in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva.
Amgen's lawsuit against Samsung Bioepis, filed on Monday, said the biosimilars would infringe 34 patents covering Amgen drugs. It requested an order blocking Samsung from making and selling the drugs and an unspecified amount of monetary damages.
Spokespeople for Amgen and Samsung Bioepis did not immediately respond to requests for comment on the complaint on Tuesday.
Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly.
Thousand Oaks, California-based Amgen told the court on Monday that Samsung had applied for permission from the U.S. Food and Drug Administration to market biosimilars of Prolia, which treats patients suffering from osteoporosis and others at high risk for bone breaks, and Xgeva, which prevents fractures in bone-cancer patients.
Amgen sold more than $2.7 billion worth of Prolia and $1.5 billion of Xgeva in the United States last year, according to a company report. The FDA granted approval in March for Sandoz to market the first biosimilars of the drugs, which will be available in the U.S. by May 2025 following the settlement of a separate patent dispute between Sandoz and Amgen.
Amgen told the court that Samsung's biosimilars would infringe patents covering Prolia and Xgeva's active ingredient denosumab and other technology related to the drugs.
The case is Amgen Inc v. Samsung Bioepis Co, U.S. District Court for the District of New Jersey, No. 1:24-cv-08417.
For Amgen: Steven Horowitz, Nathaniel Love, David Anderson, Sue Wang, Jeffrey Kushan, Joshua Fougere, Lauren Katzeff and Samuel Tiu of Sidley Austin; Siegmund Gutman and David Hanna of Mintz Levin Cohn Ferris Glovsky & Popeo
For Samsung: attorney information not yet available
Reporting by Blake Brittain in Washington
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
